Immune defects in patients with chronic lymphocytic leukemia.
Over the past decade, the introduction of nucleoside analogs and monoclonal antibodies into the treatment of patients with chronic lymphocytic leukemia (CLL) has resulted in higher rates and longer duration of response. This is a significant step towards achieving the ultimate goal of disease-eradication and improved survival. A continuing problem, however, is the susceptibility of these patients to infections. Profound dysregulation of the host immune system in patients with CLL and its impact on the clinical course of the disease are well established. A number of investigators have sought to identify the mechanisms underlying this innate immune dysfunction, which is further exacerbated by the actions of the potent therapeutic agents. The early recognition of infections as well as prophylactic administration of appropriate antibiotics has been the mainstay of managing infections in patients with CLL. Hopefully, increasing understanding of the molecular events underlying the neoplastic change in CLL will lead to more targeted and less immunosuppressive therapeutic modalities. Furthermore, the understanding of the mechanisms of immune dysfunction in CLL is of pivotal importance in the novel immune-based therapeutic strategies currently under development.
Ravandi
Farhad
F
Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 428, Houston, TX 77030-4095, USA. fravandi@mdanderson.org
O'Brien
Susan
S
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000628:therapy
D000900:Anti-Bacterial Agents; D006133:Growth Substances; D016756:Immunoglobulins, Intravenous